Twist Bioscience Corporation

NASDAQ:TWST

Medical - Diagnostics & Research

Healthcare
$116.35 +2.59%

+$2.15 today

Market cap
$7.66B
Beta
2.21
P/E (TTM)
-64.5
EPS (TTM)
-$1.32
52W Low $23.30High $88.46

Volume 2.23M

Average 1.53M

TWST Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Twist Bioscience CorporationNASDAQ: TWST

Accounts Payables · Q4 FY2026 · quarter ended Sep 2026

Accounts payables turns positive

Q4 FY2026 accounts payables was $9.35M, compared with -$284K a year earlier. Trailing-twelve-month accounts payables was $13.93M.

Context

  • Accounts payables amounted to 3.0% of revenue in FY2026, up 0.6 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $9.35M or moves back toward the trailing-twelve-month quarterly average of $3.48M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$9.35M+207.5% QoQ
Last fiscal yearSep 2026
$13.93M+49.2% YoY
LTMSep 2026
$13.93M+49.2% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3390.8%——
1 year+49.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2026
13.93M USD
Year-over-year change
+49.2%
4-year CAGR
+17.2%

Accounts Payables vs competitors

How TWST compares with its peers on the latest reported figures

  • TWST's LTM Sep 2026 accounts payables of $13.93M is the largest of the 2 companies compared; the peer median is $10.24M.
  • Its year-over-year change of +49.2% is the lowest of 2, against a peer median of +233.1%.
  • Accounts payables amounts to 3.0% of revenue for TWST, versus a peer median of 1.3%.
TWST Competitors Peer median
Accounts Payables for TWST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TWSTTwist Bioscience CorporationLTM Sep 2026$13.93M +49.2%—3.0%
RGENRepligen CorporationLTM Jun 2026$10.24M +233.1%-20.3%1.3%
Peer median (excluding TWST) $10.24M+233.1%-20.3%1.3%

Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Net Income(217.86M)(204.62M)(208.73M)(77.67M)(130.2M)
Depreciation & Amortization16.51M29.31M31.43M24.85M26.48M
Deferred Income Tax0(410K)000
Stock-Based Compensation79.66M30.28M50.93M64.46M69.86M
Change in Working Capital(5.36M)(1.01M)15.41M(12.61M)(7.83M)
Accounts Receivables(9.62M)(4.32M)8.44M(22.38M)(13.8M)
Inventory(7.54M)7.24M7.99M(4.23M)(18.1M)
Accounts Payables7.38M(2.51M)(11.81M)9.33M13.93M
Other Working Capital4.42M(1.42M)10.79M4.67M10.14M
Other Non-Cash Items2.66M3.98M46.86M(46.66M)265K
Operating Cash Flow(124.39M)(142.47M)(64.09M)(47.63M)(41.43M)
Capital Expenditures(101.86M)(27.78M)(5.08M)(28M)(47.58M)
Acquisitions (Net)(8.16M)5.86M02.5M0
Purchases of Investments(217.64M)(76.35M)(51.91M)(49.39M)(47.9M)
Sales of Investments100.48M154.74M53.91M50.14M49.35M
Other Investing Activities(5.76M)(5.86M)00(6.95M)
Investing Cash Flow(232.93M)50.61M(3.07M)(24.76M)(53.09M)
Debt Repayment(1.56M)0000
Common Stock Issued269.82M0013.56M446.72M
Common Stock Repurchased(7.75M)(4.41M)(3.98M)(16K)(42K)
Dividends Paid00000
Other Financing Activities10.02M5.32M10.87M15M0
Financing Cash Flow270.53M911K6.89M28.54M446.68M
Effect of Forex Changes(319K)(27K)126K583K24K
Net Change in Cash(87.1M)(90.98M)(60.15M)(43.27M)352.18M
Free Cash Flow(226.24M)(170.25M)(69.17M)(75.63M)(89.01M)

Twist Bioscience Corporation

NASDAQ:TWST

Intrinsic Alpha fair value

Locked

Current Price

$116.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.